Calithera to acquire 2 drug compounds from Takeda in cash-stock deal

October 18, 2021, 1:34 pm

≫ Next: DelveInsight Business Research, LLP: CDKL5 Deficiency Disorder Market to Witness Upsurge in Growth, Assesses DelveInsight | Key Companies in the Market - Jazz, Stoke, Epygenix, Zogenix, UCB Pharma, Takeda, Eisai, Longboard, Marinus

$

0

0

---

DelveInsight Business Research, LLP: CDKL5 Deficiency Disorder Market to Witness Upsurge in Growth, Assesses DelveInsight | Key Companies in the Market - Jazz, Stoke, Epygenix, Zogenix, UCB Pharma, Takeda, Eisai, Longboard, Marinus

June 6, 2023, 8:06 am

≫ Next: Takeda Pharmaceutical Company Limited: Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency

≪ Previous: Calithera to acquire 2 drug compounds from Takeda in cash-stock deal

$

0

0

The dynamics of the CDKL5 deficiency disorder market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incre...

Takeda Pharmaceutical Company Limited: Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency

June 15, 2023, 7:36 am

≫ Next: HUTCHMED (China) Limited: Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency

≪ Previous: DelveInsight Business Research, LLP: CDKL5 Deficiency Disorder Market to Witness Upsurge in Growth, Assesses DelveInsight | Key Companies in the Market - Jazz, Stoke, Epygenix, Zogenix, UCB Pharma, Takeda, Eisai, Longboard, Marinus

$

0

0

- Application Includes Data from Phase 3 FRESCO-2 and FRESCO Clinical Trials, which Demonstrated Superiority of Fruquintinib Plus Best Supportive Care (BSC) vs. Placebo plus BSC for Adult Patients...

HUTCHMED (China) Limited: Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency

June 15, 2023, 7:36 am

≫ Next: HUTCHMED (China) Limited: HUTCHMED and Takeda Announce Publication of Phase III FRESCO-2 Results in The Lancet

≪ Previous: Takeda Pharmaceutical Company Limited: Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency

$

0

0

- Application Includes Data from Phase III FRESCO-2 and FRESCO Clinical Trials, which Demonstrated Superiority of Fruquintinib Plus Best Supportive Care ("BSC") vs. Placebo plus BSC for Adult Pati...

HUTCHMED (China) Limited: HUTCHMED and Takeda Announce Publication of Phase III FRESCO-2 Results in The Lancet

June 15, 2023, 5:36 pm

≫ Next: Takeda Pharmaceutical Company Limited: Takeda und HUTCHMED geben die Genehmigung des Zulassungsantrags für Fruquintinib zur Behandlung von metastasierendem Dickdarmkrebs durch die Europäische Arzneimittelagentur bekannt

≪ Previous: HUTCHMED (China) Limited: Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency

$

0

0

- Publication shows FRESCO-2 demonstrated treatment with fruquintinib reduced the risk of death by 34% in previously treated metastatic colorectal cancer (0.66 HR) - - Data support regulatory subm...

Takeda Pharmaceutical Company Limited: Takeda und HUTCHMED geben die Genehmigung des Zulassungsantrags für Fruquintinib zur Behandlung von metastasierendem Dickdarmkrebs durch die Europäische Arzneimittelagentur bekannt

June 15, 2023, 6:36 pm

≫ Next: Takeda Pharmaceutical Company Limited: Takeda und HUTCHMED melden Veröffentlichung der Ergebnisse der Phase-3-Studie FRESCO-2 in The Lancet

≪ Previous: HUTCHMED (China) Limited: HUTCHMED and Takeda Announce Publication of Phase III FRESCO-2 Results in The Lancet

$

0

0

- Antrag umfasst Daten aus den klinischen Phase-3-Studien FRESCO-2 und FRESCO, die die Überlegenheit von Fruquintinib plus beste unterstützende Behandlung (BSC) im Vergleich zu Placebo plus BSC be...

Takeda Pharmaceutical Company Limited: Takeda und HUTCHMED melden Veröffentlichung der Ergebnisse der Phase-3-Studie FRESCO-2 in The Lancet

June 16, 2023, 6:54 pm

≪ Previous: Takeda Pharmaceutical Company Limited: Takeda und HUTCHMED geben die Genehmigung des Zulassungsantrags für Fruquintinib zur Behandlung von metastasierendem Dickdarmkrebs durch die Europäische Arzneimittelagentur bekannt

$

0

0

Veröffentlichung zeigt in der Studie FRESCO-2 für die Behandlung mit Fruquintinib nachgewiesene Senkung des Sterberisikos um 34 beim vorbehandelten metastasierten Darmkrebs (HR 0,66) Die Daten die...